Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5
- PMID: 21351148
- DOI: 10.1002/jbmr.376
Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5
Abstract
Patients with an activation mutation of the Lrp5 gene exhibit high bone mass (HBM). Limited information is available regarding compartment-specific changes in bone. The relationship between the phenotype and serum serotonin is not well documented. To evaluate bone, serotonin, and bone turnover markers (BTM) in Lrp5-HBM patients, we studied 19 Lrp5-HBM patients (T253I) and 19 age- and sex-matched controls. DXA and HR-pQCT were used to assess BMD and bone structure. Serum serotonin, sclerostin, dickkopf-related protein 1 (DKK1), and BTM were evaluated. Z-scores for the forearm, total hip, lumbar spine, forearm, and whole body were significantly increased (mean ± SD) between 4.94 ± 1.45 and 7.52 ± 1.99 in cases versus -0.19 ± 1.19 to 0.58 ± 0.84 in controls. Tibial and radial cortical areas, thicknesses, and BMD were significantly higher in cases. In cases, BMD at the lumbar spine and forearm and cortical thickness were positively associated and trabecular area negatively associated with age (r = 0.49, 0.57, 0.74, and -0.61, respectively, p < .05). Serotonin was lowest in cases (69.5 [29.9-110.4] ng/mL versus 119.4 [62.3-231.0] ng/mL, p < .001) and inversely associated with tibial cortical density (r = -0.49, p < .05) and directly with osteocalcin (OC), bone-specific alkaline phosphatase (B-ALP), and procollagen type 1 amino-terminal propeptide (PINP) (r = 0.52-0.65, p < .05) in controls only. OC and S-CTX were lower and sclerostin higher in cases, whereas B-ALP, PINP, tartrate-resistant acid phosphatase (TRAP), and dickkopf-related protein 1 (DKK1) were similar in cases and controls. In conclusion, increased bone mass in Lrp5-HBM patients seems to be caused primarily by changes in trabecular and cortical bone mass and structure. The phenotype appeared to progress with age, but BTM did not suggest increased bone formation.
Copyright © 2011 American Society for Bone and Mineral Research.
Similar articles
-
New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.Bone. 2019 Oct;127:228-243. doi: 10.1016/j.bone.2019.05.003. Epub 2019 May 11. Bone. 2019. PMID: 31085352
-
Elevated circulating Sclerostin concentrations in individuals with high bone mass, with and without LRP5 mutations.J Clin Endocrinol Metab. 2014 Aug;99(8):2897-907. doi: 10.1210/jc.2013-3958. Epub 2014 Feb 25. J Clin Endocrinol Metab. 2014. PMID: 24606091 Free PMC article.
-
Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin.J Bone Miner Res. 2010 Mar;25(3):673-5. doi: 10.1002/jbmr.44. J Bone Miner Res. 2010. PMID: 20200960
-
Novel mutation in LRP5 gene cause rare osteosclerosis: cases studies and literature review.Mol Genet Genomics. 2023 May;298(3):683-692. doi: 10.1007/s00438-023-02008-2. Epub 2023 Mar 27. Mol Genet Genomics. 2023. PMID: 36971833 Free PMC article. Review.
-
MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis.Eur J Endocrinol. 2017 Mar;176(3):R137-R157. doi: 10.1530/EJE-16-0652. Eur J Endocrinol. 2017. PMID: 28049653 Review.
Cited by
-
Associations of LRP5 Gene With Bone Mineral Density, Bone Turnover Markers, and Fractures in the Elderly With Osteoporosis.Front Endocrinol (Lausanne). 2020 Sep 25;11:571549. doi: 10.3389/fendo.2020.571549. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33101205 Free PMC article.
-
LRP6 High Bone Mass Characterized in Two Generations Harboring a Unique Mutation of Low-Density Lipoprotein Receptor-Related Protein 6.JBMR Plus. 2023 Mar 2;7(4):e10717. doi: 10.1002/jbm4.10717. eCollection 2023 Apr. JBMR Plus. 2023. PMID: 37065631 Free PMC article.
-
Serum serotonin levels and bone in rheumatoid arthritis patients.Rheumatol Int. 2017 Nov;37(11):1891-1898. doi: 10.1007/s00296-017-3836-9. Epub 2017 Oct 9. Rheumatol Int. 2017. PMID: 28993870
-
Potential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosis.Curr Osteoporos Rep. 2012 Mar;10(1):93-100. doi: 10.1007/s11914-011-0086-8. Curr Osteoporos Rep. 2012. PMID: 22210558 Review.
-
Treatment of ankylosing spondylitis with TNFα inhibitors does not affect serum levels of tryptophan metabolites.Inflammopharmacology. 2023 Oct;31(5):2393-2400. doi: 10.1007/s10787-023-01317-7. Epub 2023 Aug 30. Inflammopharmacology. 2023. PMID: 37646896 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials